Pharma major Dr. Reddy’s Laboratories has announced the re-launch of generic Isotretinoin capsules USP, 10 mg, 20 mg, 30 mg and 40 mg in the US Market on Tuesday.
The drug Zenatane (Isotretinoin Capsules, USP), is a generic therapeutic equivalent of Accutane, approved by the United States Food and Drug Administration (USFDA) is a prescription drug primarily used to treat severe acne. The product is launched under an approved Risk Evaluation and Mitigation Strategy (REMS) program.
Customer and patients will benefit from this launch as they had witnessed limited supply of the product in the market, said the company’s press release. Zenatane is the first softgel product commericalised from a Dr. Reddy’s owned manufacturing plant in the US market. The drug is available in 30-count blister packages of 10 mg, 20mg, 30 mg, and 40 mg capsules.
Total branded and generic sales of Zenatane in the US market was approximately US$525 million MAT for the 12 months ended March 2019, as per IQVIA Health data.
On Tuesday, at 10:40 hours, the stock of Dr. Reddy’s Laboratories was quoting Rs. 2,689.15 per share, down by Rs. 29.75 or 1.09 per cent on BSE.
